London

Researchers are evaluating the use of 3D ultrasound imaging to guide standard care procedures such as ablation or biopsies of liver or kidney tumours. This observational study compares 3D ultrasound with conventional 2D ultrasound and checks the imaging results against pre- and post-procedure CT scans to assess how well tumours are removed or targeted during biopsies. The 3D ultrasound method uses a special assembly to move the ultrasound transducer in precise steps, creating detailed 3-dimensional images from multiple 2D images. During the study, patients undergoing liver or kidney tumour ablation or biopsy will be imaged using both standard care and 3D ultrasound devices. These devices record image data passively while the medical procedures are performed. The 3D ultrasound images are processed with specialized software to create volumes that allow viewing the area of interest from different angles. This imaging will be compared with CT images to verify the accuracy of tumour removal or biopsy targeting. Participants will be imaged by physicians during their scheduled ablation or biopsy procedures. The study involves collecting ultrasound image data during the treatment and analyzing these images afterward. Researchers will review the guidance and targeting accuracy of the needles used during these procedures as the primary outcome. The study is conducted by Western University, Canada, and patients who are well enough to consent and undergoing these standard care procedures are eligible to participate.

Researchers are evaluating how a 12-week daily inhaler therapy combining fluticasone furoate, umeclidinium, and vilanterol affects adults aged 50 to 85 with moderate to severe COPD. The study includes equal numbers of males and females with persistent symptoms and compares those at low and high risk of COPD flare-ups. It aims to understand if this triple therapy improves lung ventilation as measured by 129-Xenon MRI and how this relates to lung function tests. Participants will use a single Ellipta inhaler containing the three medications once daily for 12 weeks, with an optional additional 48 weeks of treatment. They will attend two main visits at baseline and after 12 weeks, with an optional third visit at 48 weeks to assess longer-term effects. The study observes participants responses during and after therapy. During visits, participants undergo various lung function tests including spirometry, plethysmography, oscillometry, and exhaled nitric oxide measurement. They will have 129-Xe MRI scans and chest CT scans before and after bronchodilator use. Questionnaires assessing respiratory symptoms, health status, and exertion are completed, along with a blood draw for inflammatory markers. Researchers measure ventilation defect percentage and lung function changes to evaluate therapy effects over time.

Researchers are investigating the use of 3D ultrasound imaging during brachytherapy treatment for gynecological cancers, including primary or recurrent vaginal, endometrial, and cervical cancers. This study aims to improve needle placement accuracy in interstitial or intra-cavitary brachytherapy, which is important for delivering adequate radiation doses to tumors while protecting healthy pelvic organs. Currently, there is no standard real-time image guidance for needle insertion in these procedures, which this research seeks to address. The study involves patients receiving gynecological brachytherapy using a device-based approach, where needles and applicators are inserted under general anesthesia with guidance from clinical exams and pre-procedure MRI. An investigational 3D ultrasound device will be used during the procedure to provide real-time volumetric imaging of needle pathways, improving upon the limitations of standard 2D ultrasound. After the procedure, CT scans are performed for radiation planning. Participants will undergo imaging assessments including MRI before treatment and CT after treatment, with the main focus on measuring the accuracy of needle placement over a 16-month period. The study team will evaluate how effectively the 3D ultrasound helps avoid needle insertion into pelvic organs and optimizes tumor dose coverage. Patient safety and treatment monitoring will be conducted alongside these measurements within the study timeline.

Researchers are investigating new treatments for metastatic cervical cancer, which is cancer that has spread beyond the cervix, the lower part of the uterus. This study evaluates the safety and effectiveness of the antibody drug conjugate sacituzumab tirumotecan sac-TMT combined with pembrolizumab and bevacizumab. The goal is to find out if these treatments, given together or with some variations, help patients live longer or delay cancer progression compared to standard care. The study has two parts. In Part 1, participants receive sac-TMT, pembrolizumab, and bevacizumab together to assess safety. In Part 2, all participants first get standard induction treatment with pembrolizumab, paclitaxel, and cisplatin or carboplatin, possibly with bevacizumab. Those whose cancer does not worsen then enter maintenance treatment, where they are randomly assigned to receive either pembrolizumab alone or sac-TMT plus pembrolizumab, with optional bevacizumab. Participants are involved for up to about 20 months during maintenance treatment after up to 4 months of induction. The study monitors safety by tracking side effects and treatment discontinuations. Effectiveness is measured by progression-free survival and overall survival up to several years. Quality of life and physical functioning are also assessed through questionnaires. Treatments and evaluations occur through regular intravenous infusions and periodic monitoring visits.

Testicular cancer is a rare adult cancer but the most common solid tumor in young men, with about 90% being germ cell tumors classified as seminoma or non-seminoma. Around 20% of seminoma patients have clinical stage II disease with limited retroperitoneal lymph node metastases. This trial explores an alternative to standard radiotherapy or chemotherapy treatments, which carry risks of serious short- and long-term side effects, by evaluating the role of surgery called Primary Retroperitoneal Lymph Node Dissection RPLND.

Researchers are evaluating the efficacy and safety of trontinemab in people with early symptomatic Alzheimers disease, ranging from mild cognitive impairment to mild dementia due to Alzheimers. This Phase III trial aims to understand how trontinemab affects cognitive decline and disease progression in this population. Participants are randomly assigned to receive either intravenous trontinemab or a placebo in a parallel-group design. Treatment is administered by IV infusion, and the effects are compared over a period of 72 weeks. The study includes comprehensive safety and efficacy assessments throughout this period. During the 72 weeks of the study, participants will undergo various evaluations including cognitive tests such as the Clinical Dementia Rating-Sum of Boxes CDR-SB, Alzheimers Disease Assessment Scales, brain imaging with PET and MRI scans, and biomarker measurements in cerebrospinal fluid and blood. Safety monitoring includes tracking adverse events, infusion reactions, and antibody development. The study requires participants to have a study partner and to complete all study procedures over this time.

Researchers are studying how propylene glycol PG from beverages affects its levels in the blood of healthy adults. The study aims to find the highest concentration Cmax of PG in the serum after drinking one, two, or three PG-containing beverages. The goal is to understand the safety margin of PG exposure in healthy people by measuring how their bodies process this ingredient. Participants will consume a PG-containing beverage in doses of 12 ounces at three visits once, twice, and three times the amount. These drinks are taken with standardized meals under staff supervision, and only water is allowed besides the study drink. This sequential dosing occurs at visits 2, 4, and 6, with each beverage consumed within 15 minutes alongside the meal. During the study, participants will have blood samples taken to measure PG and related blood markers over 24 hours after dosing. They will also provide urine pregnancy tests if applicable, record their food and beverage intake in diaries, and have vital signs monitored. The main measurement is the peak PG level in serum, with additional assessments like blood osmolality and lactate concentrations taken at multiple time points after dosing. Total participation time covers all scheduled visits and assessments.

Researchers are investigating the effects of Lysoveta, a hydrolyzed krill oil supplement rich in omega-3 fatty acids, on cognitive function in healthy adults aged 50 to 75 who experience self-perceived memory problems. This randomized, placebo-controlled, triple-blind trial aims to compare the impact of Lysoveta versus a placebo on episodic, working, and spatial memory using the Computerized Mental Performance Assessment System COMPASS. Participants are randomly assigned to one of two groups one group receives three capsules daily containing 500 mg each of Lysoveta, while the other group takes placebo capsules containing a mix of medium-chain triglyceride, maize, olive, and palm kernel oils. The study lasts for 112 days, during which participants complete questionnaires to assess cognitive performance and mood. Throughout the trial, participants undergo various assessments including memory, executive function, reaction time, mood, omega-3 status, and serum brain-derived neurotrophic factor BDNF levels. They will complete questionnaires, records, and diaries related to their cognitive and mood status. Safety and adherence are monitored, and the main outcome is the change in memory performance from baseline to day 112.

Researchers are evaluating the safety and effectiveness of AMPK Chargeae, a dietary supplement, alone and combined with semaglutide injections, in adults with prediabetes or Type 2 Diabetes. This randomized, single-blind, controlled trial aims to compare changes in fasting blood glucose, fasting insulin, and hemoglobin A1c HbA1c after 84 days of treatment with these two approaches. Participants will take AMPK Chargeae twice daily on an empty stomach, holding it in the mouth before swallowing. Some participants will also receive weekly subcutaneous injections of semaglutide, starting at 0.25 mg for four weeks, then increasing to 0.5 mg for the rest of the 84-day period. The study compares these two groups to assess differences in blood sugar control. During the study, participants will undergo regular assessments of blood glucose, insulin levels, HbA1c, and other markers related to insulin resistance, cholesterol, inflammation, body weight, and cardiovascular risk. These measures will be taken at baseline, day 42, and day 84. Participants will complete questionnaires and diaries and attend clinic visits to monitor their progress and safety throughout the trial, which starts in February 2026 and ends in September 2026.

Researchers are evaluating two investigational drinks to see how they affect hydration after exercise in healthy adults who are recreationally active. The study aims to find out if these drinks, compared to control beverages, cause differences in blood hematocrit and serum osmolality at 0.5, 2, 4, and 8 hours after exercise. This is a randomized, triple-blind crossover trial sponsored by Chobani, focusing on post-exercise hydration support. Participants will consume one of four beveragestwo investigational potassium drinks Potassium15 and Potassium10, plain water, or a marketed sports beverage Gatorade Fruit Punchimmediately after exercise. Each drink is consumed in a 591 mL bottle within 10 minutes under clinic supervision. The crossover design means participants will try each beverage in separate visits, allowing comparison of their hydration effects. During the study, participants will complete an exercise challenge and record their food and beverage intake. Researchers will monitor changes in blood hematocrit, serum osmolality, and other hydration-related measures like urine volume, sodium, potassium, and body water at multiple times post-exercise. Questionnaires and diaries will track adherence and lifestyle. The study runs from May 2026 to August 2026, with healthy adults aged 18 to 65 years eligible to participate.